Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dominantly Inherited Alzheimer Network (DIAN) (DIAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00869817
Recruitment Status : Recruiting
First Posted : March 26, 2009
Last Update Posted : July 16, 2019
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Washington University School of Medicine

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Condition or disease
Alzheimer's Disease

Detailed Description:

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested:

  • First, that there is a period of preclinical (presymptomatic) AD in individuals who are destined to develop early-onset dementia (gene carriers) that can be detected by changes in biological fluids and in neuroimaging correlates in comparison with individuals who will not develop early-onset dementia (non-carriers).
  • Second, because all identified causative mutations for AD affect the normal processing of amyloid precursor protein (APP) and increase brain levels of amyloid-beta 42 (Aβ42), the sequence of preclinical changes initially will involve Aβ42 (production and clearance; reduced levels in cerebrospinal fluid [CSF]), followed by evidence for cerebral deposition of Aβ42 (amyloid imaging), followed by cerebral metabolic activity (functional imaging), and finally by regional atrophy (structural imaging).
  • Finally, that the phenotype of symptomatic early-onset familial AD, including its clinical course, is similar to that of late-onset "sporadic" AD.

The following specific aims will be used to test these hypotheses:

  1. Maintain the established international DIAN registry of individuals (mutation carriers and non-carriers; pre-symptomatic and symptomatic) who are biological adult children of a parent with a known causative mutation for AD in the APP, PSEN1, or PSEN2 genes and assess participants every 2 years with the uniform DIAN protocol.

  2. Maintain the integrated DIAN database and biospecimen repository to disseminate data and tissue to qualified investigators (within and outside of DIAN) in a user-friendly manner and to permit analyses within, between, and among the various data domains that will include:

    1. In asymptomatic mutation carriers (using non-carriers as controls), determine the temporal ordering and rate of intraindividual change in clinical, cognitive, behavioral, imaging, and fluid biomarkers of AD prior to estimated age of symptom onset.
    2. In symptomatic mutation carriers, compare the clinical and neuropathological phenotypes of ADAD to those of LOAD, using datasets such as ADNI.
  3. Utilize the DIAN cohort and its database and biospecimen repository to support new scientific studies, including use of exome chip technology to examine potential modifiers of age at symptomatic onset, exploratory investigation of new biomarker analytes, imaging modalities and techniques, perform exploratory genetic analysis to test whether novel AD genes identified through GWAS and sequencing of late onset AD cases also influence variation in age at onset of changes in biomarker endophenotypes in FAD kindred, and generate genome-wide DNA methylation data for pilot study and perform exploratory analyses to look for changes in DNA methylation in longitudinal samples from DIAN participants.
  4. Provide genetic counseling to any and all DIAN participants who wish to learn their mutation status and, for those who decide to learn their status after counseling, provide genetic testing by Clinical Laboratory Improvement Amendments (CLIA) - approved laboratories (i.e., outside of DIAN).
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 700 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dominantly Inherited Alzheimer Network (DIAN)
Study Start Date : January 2009
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1
Mutation Positive
2
Mutation Negative


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Positive predictive power of a biomarker or group of biomarkers [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent. ]
  2. Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent ]
  3. Clinical markers also examined from clinical interview and cognitive testing [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent ]

Biospecimen Retention:   Samples With DNA
buffy coat, plasma, cerebral spinal fluid

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Mutation carriers and non-carriers from families with a mutation (which is different from the genetic risk factor Apo-E4) known to cause Alzheimer's disease.
Criteria

Inclusion Criteria:

  • Written informed consent obtained from participant and collateral source prior to any study-related procedures.
  • Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
  • Cognitively normal. Primary enrollment will focus on recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with very mild, mild, or moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
  • Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
  • Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.

Exclusion Criteria:

  • Under age 18
  • Medical or psychiatric illness that would interfere in completing initial and follow-up visits
  • Requires nursing home level care
  • Has no one who can serve as a study informant
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00869817


Contacts
Layout table for location contacts
Contact: DIAN Global Coordinator 314-747-1940
Contact: Laura Swisher, MS 314-747-1940

Locations
Layout table for location information
United States, Florida
Mayo Clinic Jacksonville Recruiting
Jacksonville, Florida, United States, 32224
Contact: Sochenda Chea, BHA CRC    904-953-3234    chea.sochenda@mayo.edu   
Principal Investigator: Neil R. Graff-Radford, MD         
United States, Indiana
Indiana University-Indiana Alzheimer Disease Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jill Buck, RN    317-963-1847    jilmbuck@iu.edu   
Principal Investigator: Bernardino Ghetti, MD         
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Paige Sparks, BA    617-643-7799    kpsparks@bwh.harvard.edu   
Principal Investigator: Jasmeer Chhatwal, MD, PhD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63108
Contact: Wendy Sigurdson, RN, MPH    314-362-2256    sigurdsonw@neuro.wustl.edu   
Contact: Tamara Donahue, RN, MS    314-362-2147    donahuet@neuro.wustl.edu   
Principal Investigator: Randall Bateman, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Katie Neimeyer    212-305-5909    Kn2416@cumc.columbia.edu   
Principal Investigator: James Noble, MD         
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15260
Contact: Zana Ikonomovic, MD    412-692-2740    ikonomovics@upmc.edu   
Principal Investigator: Sarah Berman, MD, PhD         
United States, Rhode Island
Butler Hospital Recruiting
Providence, Rhode Island, United States, 02906
Contact: Courtney Bodge, PhD    401-455-6403    cbodge@butler.org   
Principal Investigator: Stephen Salloway, MD         
Argentina
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa Recruiting
Buenos Aires, Argentina
Contact: Patricio Chrem, MD    20565342    pchremmendez@fleni.org.ar   
Principal Investigator: Ricardo Allegri, MD, PhD         
Australia, New South Wales
Neuroscience Research Australia Recruiting
Sydney, New South Wales, Australia, 2031
Contact: William S. Brooks, MBBS, MPH    +612 9399 1101    w.brooks@NeuRA.edu.au   
Principal Investigator: Peter Schofield, PhD, DSc         
Australia, Victoria
Mental Health Research Institute, University of Melbourne Active, not recruiting
Melbourne, Victoria, Australia, 3130
Australia, Western Australia
Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University Recruiting
Perth, Western Australia, Australia, 6009
Contact: Kevin Taddei    +61-(0)8-6304-5107    k.taddei@ecu.edu.au   
Principal Investigator: Ralph Martins, PhD         
Germany
German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich Recruiting
Munich, Germany, D-81377
Contact: Siri Houeland di Bari    +49 89 4400 46458    Siri.HouelandDiBari@dzne.de   
Principal Investigator: Johannes Levin, MD, PhD         
German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen Recruiting
Tübingen, Germany, D-72076
Contact: Elke Kuder-Buletta    +49-(0)7071-2987584    Elke.Buletta@med.uni-tuebingen.de   
Principal Investigator: Mathias Jucker, PhD         
Japan
Osaka City University Recruiting
Osaka City, Japan
Contact: Hisako Fujii, PhD    +81-6-6645-3443    hfujii@med.osaka-cu.ac.jp   
Principal Investigator: Hiroyuki Shimada, MD, PhD         
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Songpa-Gu, Korea, Republic of, 05505
Contact: Jee Hoon Roh, MD, PhD    82-2-3010-3443    roh@amc.seoul.kr   
Principal Investigator: Jae Hong Lee, MD, PhD         
United Kingdom
Institute of Neurology, Queen Square Recruiting
London, United Kingdom, WC1N 3BG
Contact: Jane Douglas, RN MPhil.    0044 (0)845 155 5000 ext 723560    jdouglas@drc.ion.ac.uk   
Principal Investigator: Martin Rossor, MD         
Sponsors and Collaborators
Washington University School of Medicine
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Randall J. Bateman, MD Washington University School of Medicine
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00869817    
Other Study ID Numbers: IA0147
U19AG032438 ( U.S. NIH Grant/Contract )
First Posted: March 26, 2009    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019
Keywords provided by Washington University School of Medicine:
Alzheimer's disease
antecedent biomarkers
Amyloid Precursor Protein (APP) mutation
 presenilin I (PS1) mutation
presenilin 2 (PS2) mutation
Autosomal Dominant Alzheimer's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders